Pathology Diagnostics Ltd

Pathology Diagnostics Ltd (PDL) has experienced recent company growth in size and structure, moving to new premises with state of the art laboratory facilities.

Pathology Diagnostics Ltd is one of the earliest SME recipients of the £180 million Technology Strategy Board (the UK’s Innovation Agency) Biomedical Catalyst funding programme; winning a Biomedical Catalyst feasibility award in the second round.

Pathology Diagnostics Ltd contributes as expert advisor to groundbreaking Medical Research Council (MRC) review of UK molecular pathology services.

Solving the problem of PD-L1 measurement using antibody based techniques.

Immunotherapies were one of the highlights of the ASCO 2014 meeting.

Senior technical management staff from Pathology Diagnostics attended the recent DakoLink-UP Scientific Symposium held in York in June 2014.

Due to the recent rapid growth of Pathology Diagnostics, the advanced laboratory staining biomarker test portfolio of the organisation has grown at an extremely impressive rate, with the number of biomarkers validated now reaching over 370.

Emerging onto social media, enables Pathology Diagnostics to open up a new channel of communication and showcase their industry insight.